Essential thrombocythemia after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Allogeneic transplant recipients are at high risk of developing secondary malignancies as a late complication of therapy. We report a case of essential thrombocythemia occurring 8 years following bone marrow transplantation (BMT) for chronic myelogenous leukemia.
Khoury
H
H
Washington University School of Medicine, Division of Bone Marrow Transplantation and Stem Cell Biology, St. Louis, MO 63110, USA.
Adkins
D
D
Zehnbauer
B
B
Goodnough
L
L
Brown
R
R
Safdar
S
S
DiPersio
J F
JF
D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008297:Male; D013922:Thrombocytosis / Q000209:etiology*; D018183:Transplantation Chimera; D014184:Transplantation, Homologous